Dystonia
The most common surgical treatment for Parkinson’s disease is deep brain stimulation (DBS). Similar to available drug treatments, DBS does not slow down the disease or restore sick and dying nerve cells affected by Parkinson’s disease, but rather offers symptomatic…
Today’s Wall Street Journal reports on promising new research directions to treat dyskinesia (subscription required), the disabling side effect of long-term dopamine replacement therapy. “As they continue to wait for a cure, patients with Parkinson’s disease may soon see more…
Addex Pharmaceuticals is moving forward with a Phase IIa study evaluating the metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, called dipraglurant (ADX48621), in reducing levodopa-induced dyskinesia in patients with Parkinson’s disease (PD). The study is not impacted by Merck’s…
